The synovial sarcoma X breakpoint antigen 1 (SSX-1), along with other members of the SSX family frequently expressed in cancer, has been verified to be an oncoprotein involved in disease pathogenesis and a molecular therapeutic target against synovial sarcoma; hence, it may be an excellent candidate target for cancer immunotherapy 17. Here, SSX1 is linked to cancer.